The stock of Emergent Biosolutions Inc (EBS) has seen a 9.92% increase in the past week, with a 20.47% gain in the past month, and a -43.50% decrease in the past quarter. The volatility ratio for the week is 10.40%, and the volatility levels for the past 30 days are at 7.60% for EBS. The simple moving average for the past 20 days is 12.18% for EBS’s stock, with a -31.29% simple moving average for the past 200 days.
Is It Worth Investing in Emergent Biosolutions Inc (NYSE: EBS) Right Now?
Moreover, the 36-month beta value for EBS is 2.09. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for EBS is 51.95M and currently, short sellers hold a 14.93% of that float. On May 12, 2025, EBS’s average trading volume was 1.30M shares.
EBS) stock’s latest price update
Emergent Biosolutions Inc (NYSE: EBS)’s stock price has gone decline by -11.16 in comparison to its previous close of 6.36, however, the company has experienced a 9.92% increase in its stock price over the last five trading days. seekingalpha.com reported 2025-05-07 that Emergent BioSolutions Inc. (NYSE:EBS ) Q1 2025 Earnings Call May 7, 2025 5:00 PM ET Company Participants Frank Vargo – Vice President, Assistant Treasurer Joe Papa – President and Chief Executive Officer Rich Lindahl – Executive Vice President and Chief Financial Officer Conference Call Participants Jessica Fye – JPMorgan Yi Chen – H.C. Wainwright Operator Good day and thank you for standing by.
Analysts’ Opinion of EBS
Many brokerage firms have already submitted their reports for EBS stocks, with H.C. Wainwright repeating the rating for EBS by listing it as a “Buy.” The predicted price for EBS in the upcoming period, according to H.C. Wainwright is $15 based on the research report published on December 30, 2024 of the previous year 2024.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see EBS reach a price target of $16. The rating they have provided for EBS stocks is “Buy” according to the report published on August 22nd, 2024.
The Benchmark Company gave a rating of “Buy” to EBS, setting the target price at $5 in the report published on March 07th of the previous year.
EBS Trading at 7.05% from the 50-Day Moving Average
After a stumble in the market that brought EBS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.58% of loss for the given period.
Volatility was left at 7.60%, however, over the last 30 days, the volatility rate increased by 10.40%, as shares surge +32.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.97% lower at present.
During the last 5 trading sessions, EBS rose by +9.92%, which changed the moving average for the period of 200-days by -54.76% in comparison to the 20-day moving average, which settled at $5.04. In addition, Emergent Biosolutions Inc saw -40.90% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EBS starting from Fowler Neal Franklin, who sale 35,000 shares at the price of $5.83 back on Mar 12 ’25. After this action, Fowler Neal Franklin now owns 101,100 shares of Emergent Biosolutions Inc, valued at $204,050 using the latest closing price.
Zoon Kathryn C, the Director of Emergent Biosolutions Inc, sale 10,000 shares at $5.73 during a trade that took place back on Mar 12 ’25, which means that Zoon Kathryn C is holding 44,482 shares at $57,300 based on the most recent closing price.
Stock Fundamentals for EBS
Current profitability levels for the company are sitting at:
- -0.06 for the present operating margin
- 0.31 for the gross margin
The net margin for Emergent Biosolutions Inc stands at -0.18. The total capital return value is set at -0.05. Equity return is now at value -21.63, with -8.15 for asset returns.
Based on Emergent Biosolutions Inc (EBS), the company’s capital structure generated 0.58 points at debt to capital in total, while cash flow to debt ratio is standing at 0.09. The debt to equity ratio resting at 1.37. The interest coverage ratio of the stock is -0.91.
Currently, EBITDA for the company is 40.1 million with net debt to EBITDA at 14.58. When we switch over and look at the enterprise to sales, we see a ratio of 0.84. The receivables turnover for the company is 6.72for trailing twelve months and the total asset turnover is 0.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.32.
Conclusion
To wrap up, the performance of Emergent Biosolutions Inc (EBS) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
